🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07519538
Active, not recruiting Observational

Southern Sichuan HIV Cohort Study Protocol

NCT07519538 · tracked via the Priya Life Science China tracker
Sponsor
Southwest Medical University
Phase
Observational
Started
2026-04-03
Last updated
2026-04-09

Condition(s) studied

HIV - Human Immunodeficiency Virus

Study summary

Multi-source data-integrated HIV cohort in four cities of southern Sichuan, China: a mixed retrospective-prospective study protocol.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * People living with HIV (PLWH) or AIDS patients who are registered and diagnosed at the participating research centers in Luzhou, Zigong, Neijiang, or Yibin, China * Key assessment information (clinical, laboratory, or follow-up data) obtainable during the study period * Traceable medical treatment or follow-up records within the retrospective time window (1 January 2019 to 31 December 2025) * Able to understand and complete the questionnaire and provide written informed consent (for the prospective component) * Residing or visiting within the four southern Sichuan cities, or continuously managed at the local research centers Exclusion Criteria: * Missing key information that cannot be verified or supplemented from original records * Unable to complete the questionnaire and no alternative data collection method available * Obviously inconsistent or untrustworthy data that cannot be confirmed after verification * Not suitable for inclusion under ethical and compliance requirements (e.g., unable to provide consent without a legally authorized representative when required)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Southwest Medical University Luzhou Sichuan

More Southwest Medical University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07519538 on ClinicalTrials.gov ↗ ← All trials in China